INT303352

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 7.68
Pain Relevance 1.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Jag1)
Anatomy Link Frequency
muscle 7
Notch 4
obsolete 1
thick filaments 1
Jag1 (Mus musculus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 615 98.54 Very High Very High Very High
cytokine 13 96.92 Very High Very High Very High
Demyelination 15 87.24 High High
imagery 26 5.00 Very Low Very Low Very Low
Inflammation 15 5.00 Very Low Very Low Very Low
Pain 14 5.00 Very Low Very Low Very Low
Spinal cord 13 5.00 Very Low Very Low Very Low
Sciatic nerve 13 5.00 Very Low Very Low Very Low
intrathecal 10 5.00 Very Low Very Low Very Low
Osteoarthritis 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 13 99.76 Very High Very High Very High
Muscular Atrophy 117 98.68 Very High Very High Very High
Demyelinating Disease 630 98.54 Very High Very High Very High
Frailty 52 97.44 Very High Very High Very High
Disease 100 94.24 High High
Stress 14 87.28 High High
Aging 3 81.32 Quite High
Disorder Of Lipid Metabolism 45 64.00 Quite High
Hypertrophy 13 62.48 Quite High
Appetite Loss 13 51.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have shown earlier that the expression of ozz mRNA and Ozz protein increases during muscle development from embryonic day E12.5 onward [12] (Fig. 1A).
Gene_expression (expression) of Ozz protein in muscle
1) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.64 Pain Relevance 0
Ozz expression was downregulated during the phase of degeneration, but was upregulated during the regeneration phase (Fig. 1C), confirming that Ozz expression is associated with muscle development and growth.


Gene_expression (expression) of Ozz in muscle
2) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.44 Pain Relevance 0
We have shown earlier that the expression of ozz mRNA and Ozz protein increases during muscle development from embryonic day E12.5 onward [12] (Fig. 1A).
Gene_expression (expression) of ozz in muscle
3) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.64 Pain Relevance 0
Ozz expression was downregulated during the phase of degeneration, but was upregulated during the regeneration phase (Fig. 1C), confirming that Ozz expression is associated with muscle development and growth.


Gene_expression (expression) of Ozz in muscle
4) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.48 Pain Relevance 0
The latter conclusion was further supported by the pattern of Ozz expression upon injury of adult muscles with local injection of cardiotoxin.
Gene_expression (expression) of Ozz in muscles associated with injury
5) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.57 Pain Relevance 0
This model of regulated assembly and disassembly of MyHC could be envisaged also for the adult muscle, where Ozz is expressed at basal levels [12].
Gene_expression (expressed) of Ozz in muscle
6) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.09 Pain Relevance 0
We showed that Ozz and Elo C are present together with sarcomeric myosin from the earliest stages of myofibrillogenesis, but we saw no obvious increase in Ozz/MyHCemb ratio in association with the onset of peak periods of MyHCemb degradation during embryogenesis (e.g.
Gene_expression (ratio) of Ozz
7) Confidence 0.63 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
We showed that Ozz and Elo C are present together with sarcomeric myosin from the earliest stages of myofibrillogenesis, but we saw no obvious increase in Ozz/MyHCemb ratio in association with the onset of peak periods of MyHCemb degradation during embryogenesis (e.g.
Gene_expression (present) of Ozz
8) Confidence 0.63 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
Furthermore and in agreement with the observed presence of both Ozz and Elo C in purified thin-thick filaments (Fig. 5A), we found a portion of Ozz bound to Elo C within the myofibrils (P fraction) but not in the soluble (S) fraction (Fig. 5B, panel 4).
Gene_expression (presence) of Ozz in thick filaments
9) Confidence 0.63 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
Ozz expression is muscle-specific and upregulated during muscle fiber differentiation, but we show here that it is downregulated in muscle atrophy.
Gene_expression (expression) of Ozz in muscle associated with muscular atrophy
10) Confidence 0.56 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0.26 Pain Relevance 0.05
Ozz-E3 Ubiquitin Ligase Targets Sarcomeric Embryonic Myosin Heavy Chain during Muscle Development

Muscle contractile proteins are expressed as a series of developmental isoforms that are in constant dynamic remodeling during embryogenesis, but how obsolete molecules are recognized and removed is not known.

Gene_expression (expressed) of Ozz in obsolete
11) Confidence 0.56 Published 2010 Journal PLoS ONE Section Title Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
We then separated the P and S myosin preparations on gel filtration columns and assessed the levels and distribution of MyHCemb and Ozz on immunoblots of the eluted fractions probed with anti MyHCemb, anti-Ozz and anti-MLC antibodies.
Gene_expression (antibodies) of anti-Ozz
12) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
Free Ozz eluted from the column in size fragments near its monomeric molecular weight of ?
Gene_expression (eluted) of Ozz
13) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844429 Disease Relevance 0 Pain Relevance 0
Jagged-1 has been found to be highly expressed in hypertrophic astrocytes within and around active MScl plaques lacking remyelination, while, in contrast, there was negligible jagged-1 expression in remyelinated lesions suggesting involvement of the Notch pathway in remyelination in MScl [21].
Gene_expression (expressed) of Jagged-1 in Notch associated with multiple sclerosis
14) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2929207 Disease Relevance 0.68 Pain Relevance 0.24
Additionally, animal models have shown that elevated expression of Notch and jagged-1 expression does not appear to be a limiting factor in remyelination, but the animal model study reports that there were no quantitative differences in Notch1 expressing cells in slow and rapidly remyelinating lesions, indicating that Notch–Jagged signaling is not a rate-limiting determinant of remyelination in rodent models of demyelination [24].
Gene_expression (expression) of jagged-1 in Notch associated with demyelination
15) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2929207 Disease Relevance 0.59 Pain Relevance 0.22
Jagged-1 has been found to be highly expressed in hypertrophic astrocytes within and around active MScl plaques lacking remyelination, while, in contrast, there was negligible jagged-1 expression in remyelinated lesions suggesting involvement of the Notch pathway in remyelination in MScl [21].
Gene_expression (expression) of jagged-1 in Notch associated with multiple sclerosis
16) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2929207 Disease Relevance 0.67 Pain Relevance 0.24
Additionally, animal models have shown that elevated expression of Notch and jagged-1 expression does not appear to be a limiting factor in remyelination, but the animal model study reports that there were no quantitative differences in Notch1 expressing cells in slow and rapidly remyelinating lesions, indicating that Notch–Jagged signaling is not a rate-limiting determinant of remyelination in rodent models of demyelination [24].
Gene_expression (expression) of jagged-1 in Notch associated with demyelination
17) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2929207 Disease Relevance 0.59 Pain Relevance 0.22
Of these peaks 7 were identified, the most notable being protein jagged-1 (Table 2).
Gene_expression (identified) of jagged-1
18) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2929207 Disease Relevance 1.89 Pain Relevance 0.91
These cells are positive for Jagged-1 and Stro-1.
Gene_expression (positive) of Jagged-1
19) Confidence 0.01 Published 2010 Journal Stem Cells (Dayton, Ohio) Section Body Doc Link PMC3003945 Disease Relevance 0.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox